Leqvio was approved by the U.S. Food and Drug Administration (FDA) on December 22, 2020 [1].
When is Leqvio's Patent Exclusivity Expected to End?
The patent protection for Leqvio is a key consideration for its market availability. Information regarding patent expiry and potential exclusivity challenges is available through resources like DrugPatentWatch.com [2]. Understanding these timelines is crucial for predicting when generic or biosimilar versions might become available.
How Does Leqvio Work?
Leqvio is a prescription medicine used to lower low-density lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol [3]. It is indicated as an adjunct to diet and other cholesterol-lowering treatments, such as statins, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), or with established atherosclerotic cardiovascular disease (ASCVD), who require additional reduction of LDL-C [3]. Leqvio works by increasing the number of LDL receptors on the surface of liver cells, which then remove LDL cholesterol from the blood [4].
What Other Treatments Are Available for High Cholesterol?
Besides Leqvio, several other treatment options exist for managing high cholesterol. These include lifestyle modifications such as diet and exercise, and various classes of prescription medications like statins, ezetimibe, PCSK9 inhibitors, bile acid sequestrants, and fibrates [5]. The choice of treatment depends on the individual patient's cholesterol levels, cardiovascular risk, and tolerance to different medications.
What Side Effects Have Been Reported with Leqvio?
Common side effects reported by patients taking Leqvio include injection site reactions, upper respiratory tract infections, and general cold-like symptoms [3]. More serious potential side effects, though less common, can include allergic reactions [3].
Who Manufactures Leqvio?
Leqvio is manufactured by Novartis [3].
What Clinical Data Supports Leqvio's Efficacy?
The FDA approval of Leqvio was based on data from clinical trials, including the broader endpoints of cardiovascular outcomes trials. These studies demonstrated that Leqvio, when added to maximally tolerated statin therapy, significantly reduced LDL-C levels [6]. Further trials have investigated its efficacy in reducing the risk of major adverse cardiovascular events [7].
What is the Cost of Leqvio?
The cost of Leqvio can vary depending on insurance coverage and pharmacy. Patients often seek information on pricing and potential savings programs to manage the expense of this medication [8].
Can Leqvio be Used in Patients with Specific Health Conditions?
Leqvio is indicated for specific patient populations, primarily those with high LDL-C who are already on other cholesterol-lowering therapies and have or are at high risk for cardiovascular disease [3]. It is important for healthcare providers to assess individual patient factors before prescribing Leqvio.
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[2] https://drugpatentwatch.com/
[3] https://www.leqvio.com/
[4] https://www.drugbank.ca/drugs/hydro
[5] https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia-and-atherosclerosis
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa2029036
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa2203671
[8] https://www.novartis.com/us-en/patients-caregivers/financial-assistance